Radiopharm Theranostics announced it has extended its agreement with global oncology provider GenesisCare, who will support a second Radiopharm clinical trial in Australia. The trial will use Radiopharm's PSA targeting antibody to start a therapeutic Phase 1 in prostate cancer, with an expected commencement in the coming months. The innovative approach and novel mode of action compared with other treatments currently under development make Radiopharm's technology highly prospective.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.046 AUD | +2.22% | +2.22% | -37.84% |
Feb. 29 | Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study | MT |
Feb. 29 | Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-37.84% | 13.22M | |
+24.35% | 653B | |
+25.35% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+12.79% | 233B | |
+5.36% | 201B | |
-9.94% | 193B | |
-6.47% | 144B |
- Stock Market
- Equities
- RAD Stock
- News Radiopharm Theranostics Limited
- Radiopharm Extends Agreement with Genesiscare for Australian Prostate Cancer Trial